175 related articles for article (PubMed ID: 30216851)
1. Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
Savino S; Toscano A; Purgatorio R; Profilo E; Laghezza A; Tortorella P; Angelelli M; Cellamare S; Scala R; Tricarico D; Marobbio CMT; Perna F; Vitale P; Agamennone M; Dimiccoli V; Tolomeo A; Scilimati A
Eur J Med Chem; 2018 Oct; 158():184-200. PubMed ID: 30216851
[TBL] [Abstract][Full Text] [Related]
2. Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase.
De Schutter JW; Zaretsky S; Welbourn S; Pause A; Tsantrizos YS
Bioorg Med Chem Lett; 2010 Oct; 20(19):5781-6. PubMed ID: 20801032
[TBL] [Abstract][Full Text] [Related]
3. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
Wiemer AJ; Tong H; Swanson KM; Hohl RJ
Biochem Biophys Res Commun; 2007 Feb; 353(4):921-5. PubMed ID: 17208200
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
5. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
Leung CY; Park J; De Schutter JW; Sebag M; Berghuis AM; Tsantrizos YS
J Med Chem; 2013 Oct; 56(20):7939-50. PubMed ID: 23998921
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of a series of aromatic bisphosphonates.
Barney RJ; Wasko BM; Dudakovic A; Hohl RJ; Wiemer DF
Bioorg Med Chem; 2010 Oct; 18(20):7212-20. PubMed ID: 20832326
[TBL] [Abstract][Full Text] [Related]
7. A novel inhibitory mechanism of nitrogen-containing bisphosphonate on the activity of Cl- extrusion in osteoclasts.
Ohgi K; Kajiya H; Okamoto F; Nagaoka Y; Onitsuka T; Nagai A; Sakagami R; Okabe K
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jul; 386(7):589-98. PubMed ID: 23564016
[TBL] [Abstract][Full Text] [Related]
8. Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls.
De Schutter JW; Shaw J; Lin YS; Tsantrizos YS
Bioorg Med Chem; 2012 Sep; 20(18):5583-91. PubMed ID: 22884353
[TBL] [Abstract][Full Text] [Related]
9. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in understanding the mechanism of action of bisphosphonates.
Coxon FP; Thompson K; Rogers MJ
Curr Opin Pharmacol; 2006 Jun; 6(3):307-12. PubMed ID: 16650801
[TBL] [Abstract][Full Text] [Related]
11. 3D-QSAR, molecular docking, and ONIOM studies on the structure-activity relationships and action mechanism of nitrogen-containing bisphosphonates.
Liu QZ; Wang SS; Li X; Zhao XY; Li K; Lv GC; Qiu L; Lin JG
Chem Biol Drug Des; 2018 Mar; 91(3):735-746. PubMed ID: 29080272
[TBL] [Abstract][Full Text] [Related]
12. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
Dunford JE
Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
[TBL] [Abstract][Full Text] [Related]
13. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition.
Nagaoka Y; Kajiya H; Ozeki S; Ikebe T; Okabe K
J Dent Res; 2015 Apr; 94(4):594-601. PubMed ID: 25535203
[TBL] [Abstract][Full Text] [Related]
14. Approaches for Designing new Potent Inhibitors of Farnesyl Pyrophosphate Synthase.
Rodriguez JB; Falcone BN; Szajnman SH
Expert Opin Drug Discov; 2016; 11(3):307-20. PubMed ID: 26781029
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates: mode of action and pharmacology.
Russell RG
Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
[TBL] [Abstract][Full Text] [Related]
16. Synergistic Activity between Statins and Bisphosphonates against Acute Experimental Toxoplasmosis.
Li ZH; Li C; Szajnman SH; Rodriguez JB; Moreno SNJ
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559264
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic insights into protonation state as a critical factor in hFPPS enzyme inhibition.
Fernández D; Ortega-Castro J; Mariño L; Perelló J; Frau J
J Comput Aided Mol Des; 2015 Jul; 29(7):667-80. PubMed ID: 26081258
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologically Inactive Bisphosphonates as an Alternative Strategy for Targeting Osteoclasts: In Vivo Assessment of 5-Fluorodeoxyuridine-Alendronate in a Preclinical Model of Breast Cancer Bone Metastases.
Schem C; Tower RJ; Kneissl P; Rambow AC; Campbell GM; Desel C; Damm T; Heilmann T; Fuchs S; Zuhayra M; Trauzold A; Glüer CC; Schott S; Tiwari S
J Bone Miner Res; 2017 Mar; 32(3):536-548. PubMed ID: 27714838
[TBL] [Abstract][Full Text] [Related]
20. Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells.
Abe K; Yoshimura Y; Deyama Y; Kikuiri T; Hasegawa T; Tei K; Shinoda H; Suzuki K; Kitagawa Y
Int J Mol Med; 2012 Jun; 29(6):1007-15. PubMed ID: 22447156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
